For a 57‑year‑old woman with major depressive disorder and attention‑deficit/hyperactivity disorder, is viloxazine a better treatment option than bupropion?

Viloxazine vs. Bupropion for Comorbid MDD and ADHD

For a 57-year-old woman with both major depressive disorder and ADHD, bupropion is the better choice over viloxazine. Bupropion has established efficacy for both conditions with decades of safety data, while viloxazine lacks evidence for treating depression and has minimal data in adults with ADHD.

Rationale for Bupropion

Bupropion addresses both conditions simultaneously with proven efficacy. For MDD, it demonstrated significant improvement in HAMD total scores and CGI-S scores in multiple placebo-controlled trials, with a maintenance study showing significantly lower relapse rates over 44 weeks 1. For ADHD in adults, bupropion showed superiority over placebo in randomized controlled trials 2, and guidelines specifically identify it as a reasonable first-line treatment for comorbid mood disorders and ADHD 3.

The 2024 AJOG guidelines note that "bupropion is a norepinephrine and dopamine reuptake inhibitor, which has been shown to be more effective than placebo in adults with ADHD" 4. When treating comorbid MDD and ADHD, older guidelines from 2002 acknowledge that "no data support a single antidepressant to treat both ADHD and MDD," but note bupropion has "proven antidepressant activity in adults" 5.

Why Not Viloxazine

Viloxazine has no established efficacy for depression and limited adult ADHD data. While it showed statistically significant improvement in ADHD symptoms in one adult trial (AISRS score reduction: -15.5 vs -11.7 placebo, p=0.0040) 6, this represents a modest effect size. The 2024 guidelines explicitly state "there are no data available on the safety of viloxazine in the perinatal context" and recommend it only after "risk-benefit discussion acknowledging that there is no information published on its safety in pregnancy and there is limited data on its efficacy for the treatment of ADHD in adults. Alternative agents would be preferred" 4.

Viloxazine was originally an antidepressant withdrawn from markets in 2002 7, but its repurposing focused solely on ADHD—not depression. Recent pharmacology studies show it acts as a NET inhibitor with serotonergic activity 8, 9, but this mechanism hasn't translated to proven antidepressant efficacy in modern trials.

Treatment Algorithm

Step 1: Determine which condition is primary or more severe

• If MDD is severe (psychosis, suicidality, severe neurovegetative signs): Treat depression first 5
• If MDD is mild-moderate and ADHD causes significant impairment: Can address both simultaneously

Step 2: For this 57-year-old with both conditions

• Start bupropion XL 150 mg once daily for 1 week
• Titrate to 300 mg once daily (therapeutic dose for both conditions) 1
• Monitor response at 1-2 weeks, then regularly 10

Step 3: Assess response at 6-8 weeks

• If ADHD symptoms persist despite improved mood: Consider adding a stimulant (methylphenidate or amphetamine) 5
• If depression inadequately treated: Switch to or augment with an SSRI 10
• If both inadequately treated: Reassess diagnosis and consider specialist referral

Common Pitfalls

Avoid assuming viloxazine will help depression simply because it has serotonergic activity. The 2022 review notes it was "withdrawn from markets in 2002" as an antidepressant 7, and no modern trials demonstrate antidepressant efficacy.

Monitor for seizure risk with bupropion (contraindicated in seizure disorders, eating disorders, abrupt alcohol/benzodiazepine discontinuation) 1. The seizure threshold lowering is dose-dependent—stay at ≤450 mg/day.

Watch for activation/agitation in the first 1-2 weeks, particularly suicidal ideation, as required by FDA black box warning for all antidepressants 1, 10.

Don't expect immediate ADHD response—while stimulants work rapidly, bupropion's ADHD effects may take 3-4 weeks to manifest fully 2.

Adverse Effect Considerations

Bupropion's most common side effects include insomnia, headache, dry mouth, nausea, and decreased appetite 1. Notably, bupropion has lower rates of sexual dysfunction compared to SSRIs 10, which may be important for quality of life in a 57-year-old woman.

Viloxazine's adverse events in adults included insomnia (14.8%), fatigue (11.6%), nausea (10.1%), and decreased appetite (10.1%) 6. Recent FAERS database analysis identified concerning signals including suicidal ideation (EBGM=29.51), panic attacks, and homicidal ideation 11—particularly problematic in someone with existing MDD.

The evidence strongly favors bupropion for this clinical scenario, given its dual efficacy, extensive safety record, and guideline support for treating comorbid MDD and ADHD 3.